Novo-Nordisk A/S
Symbol: NVO (NYSE)
58.58
▼ (-1.01%) -0.595
Company Description:
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key Stats
- Today's Open: $58.88
- Today's High: $59.223
- Today's Low: $57.799
- Today's Volume: 11.97M
- Yesterday Close: $59.17
- Yesterday High: $59.22
- Yesterday Low: $56
- Yesterday Volume: 24.84M
- Last Min Volume: 9
- Last Min High: $58.575
- Last Min Low: $58.575
- Last Min VWAP: $58.575
Company Profile
- Name: Novo-Nordisk A/S
- Website: https://www.novonordisk.com
- Listed Date: 1981-04-30
- Location: ,
- Market Status: Active
- CIK Number: 0000353278
- SIC Code:
- SIC description:
- Market Cap: $262.92B
- Round Lot: 100
- Outstanding Shares: 4.44B
- Asset Type: ADRC
RECENT FILINGS FOR NVO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 6-K | View |
| 2025-08-19 | 6-K | View |
| 2025-08-18 | 6-K | View |
| 2025-08-14 | 6-K | View |
| 2025-08-08 | 6-K | View |
| 2025-08-08 | 6-K | View |
| 2025-08-06 | 6-K | View |
| 2025-08-04 | 6-K | View |
| 2025-07-29 | 6-K | View |
| 2025-07-29 | 6-K | View |
| 2025-06-27 | 11-K | View |
| 2025-06-27 | 11-K | View |
| 2025-06-13 | 6-K | View |
| 2025-05-30 | 144 | View |
| 2025-05-22 | SD | View |
| 2025-05-16 | 6-K | View |
| 2025-05-09 | 6-K | View |
| 2025-05-07 | 6-K | View |
| 2025-04-23 | SCHEDULE 13G/A | View |
| 2025-04-03 | 6-K | View |
Latest News on NVO